BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 11.4% in December

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 4,400,000 shares, a growth of 11.4% from the December 15th total of 3,950,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is presently 3.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered shares of BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in BioAtla during the 2nd quarter valued at $872,000. Scion Asset Management LLC purchased a new stake in shares of BioAtla in the second quarter valued at $869,000. GSA Capital Partners LLP acquired a new stake in shares of BioAtla during the third quarter valued at $623,000. Bank of Montreal Can increased its position in BioAtla by 55.1% during the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock worth $554,000 after purchasing an additional 143,521 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in BioAtla by 36.1% in the 2nd quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock valued at $59,000 after purchasing an additional 11,503 shares during the last quarter. 77.23% of the stock is owned by hedge funds and other institutional investors.

BioAtla Stock Performance

BioAtla stock opened at $0.49 on Monday. BioAtla has a fifty-two week low of $0.45 and a fifty-two week high of $4.02. The firm has a market capitalization of $23.84 million, a price-to-earnings ratio of -0.29 and a beta of 1.17. The stock’s fifty day moving average is $1.17 and its two-hundred day moving average is $1.57.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same quarter last year, the firm posted ($0.70) earnings per share. As a group, sell-side analysts forecast that BioAtla will post -1.46 EPS for the current fiscal year.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.